Damora Therapeutics, Inc. Common Stock’s (DMRA) Outperform Rating Reiterated at Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a research note issued on Tuesday, Benzinga reports. They presently have a $40.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 97.82% from the company’s previous close.

Several other analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Guggenheim increased their price target on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Friday. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has an average rating of “Buy” and an average target price of $46.50.

Damora Therapeutics, Inc. Common Stock Trading Down 2.6%

Shares of DMRA stock traded down $0.53 during trading hours on Tuesday, hitting $20.22. The company’s stock had a trading volume of 14,741 shares, compared to its average volume of 424,066. The business has a fifty day moving average of $28.18 and a 200-day moving average of $26.27. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -6.00 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a twelve month low of $3.50 and a twelve month high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.06. On average, equities analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Jennifer Jarrett purchased 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The shares were bought at an average price of $20.23 per share, with a total value of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 0.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Large investors have recently bought and sold shares of the stock. Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $42,146,000. Seven Fleet Capital Management LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $7,398,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $303,000. Finally, Arizona State Retirement System purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.